Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06844344

Diagnosing peRipheral Lung Lesions With CRYO Biopsies

Lung cancer is the leading course of cancer related deaths world-wide. Lung cancer screening will increase the number of small lung lesion in need of biopsy to confirm the diagnosis. Obtaining lung biopsies with a bronchoscopy has the lowest risk of complications (1-2%) compared to other modalities such as transthoracic needle biopsy (20%), however diagnostic yield needs improvement. Currently a diagnosis is established in 50- 70% of the bronchoscopic procedures depending on the step-up. One way to improve the yield would be by using a cryo probe through the bronchoscope which freezes a small part of the lung for extraction, and thereby provides larger biopsies for examination. This will increase the chances of obtaining sufficient material from a small lesion to determine the diagnosis.

The DR CRYO study will compare cryo biopsies to forceps biopsies for the diagnosis of peripheral lung lesions.

We hope that the cryo biopsies can improve the diagnostic capabilities of bronchoscopy and provide better biopsies for tumor marker analyses. The project is relevant both for patients undergoing diagnostic work-up for lung cancer in early stages .

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Næstved Hospital, Næstved, Region Sjælland, Denmark

Loading trial locations.

About this study

Background:

Lung cancer is currently the leading cause of cancer related deaths world-wide [1]. Approximately 5000 people are diagnosed with lung cancer each year in Denmark [2]. Lung cancer is often detected in late stages of the disease, which are rarely curable and have a poor prognosis [3]. Currently, early stages of lung cancer are often detected incidentally on a computed tomography (CT) scan as a solitary lung lesion [4]. Screening for lung cancer has the possibility to reduce lung cancer mortality, however a screening program will produce a large increase in CT scans with lung lesions [5, 6]. Tissue sampling is one of the corner stones for correctly diagnosing cancer in a patient. Obtaining tissue from the lungs is challenging since the lungs are difficult to access and biopsies comes with risk of complications.

Tissue samples can be acquired either by removing part of the lung surgically, by performing a needle biopsy through the chest wall or by using a bronchoscope (i.e. by endoscopy)-. The latter has the lowest risk of complications, but currently the diagnostic yield is lower than the other two methods. The low risk profile is an advantage in an increasing elderly population, where improvements in the diagnostic capabilities would be of great value to the patients.

Cryo freezing probes enable sampling from the lung parenchyma by freezing a small tissue area which is then extracted via the bronchoscope. The technology was initially invented to provide larger tissue samples for the diagnosis of interstitial lung disease, but may also be of great value for collecting tissue from cancerous disease since cryo biopsies are generally larger and less crushed than traditional biopsies.

Few studies regarding cryo biopsy for sampling cancer in the lungs exists, however initial trials demonstrates higher diagnostic yield and an increase in sufficient material for tumor marker analysis[9, 10].

Hypothesis:

  • Larger biopsies (i.e., cryo biopsies) will increase the diagnostic yield by allowing for sub-optimal sampling position
  • Cryo biopsies are larger and less crushed than forceps biopsies and could therefore increase benign yield to rule out cancer in patients with cancer suspected lesions
  • Using the 1.1 freezing probe for diagnosing malignancy is safe and feasible under conscious sedation.

Objectives:

  • Compare the diagnostic yield of cryo biopsies with forceps biopsies in lesions suspected of malignancy
  • Compare the benign yield/ malignant yield of cryo biopsies with forceps biopsies
  • Compare the number of samples with sufficient material for Next Generation Sequencing (NGS) testing
  • Assess the safety of using the 1.1 mm freezing probe without general anesthesia, tracheal tube or endobronchial blocker.
  • Develop a grading system for endoscopic biopsies to ensure standardized and reproducible assessment.

Method:

This study will be conducted as a randomized clinical trial according to CONSORT guidelines (multicenter) study at Center for Lung Cancer at Odense University Hospital, Bispebjerg Hospital, and Næstved Hospital in collaboration with the Department of Pathology at Odense University Hospital [11] .

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • - Patients undergoing diagnostic work-up for lung cancer due to a lung lesion surrounded by normal lung tissue (identified by CT)
  • Age 18 or above
  • Bronchoscopy with planned forceps sampling from the lesion

Exclusion criteria

  • - Pregnancy
  • Not able to provide informed consent.

Treatment and study plan

forceps biopsies

Diagnostic Test

5 forceps biopsies

Cryo biosies

Diagnostic Test

5 cryo biopsies

Primary outcomes

  1. Diagnostic yield

    Time frame: One week after initial study procedure

    • Total diagnostic yield, being defined as a tissue biopsy allowing a definite diagnosis of either a malignant or benign condition in the lung in proportion to the total number of procedures performed.

Secondary outcomes

  1. Malignant yield

    Time frame: One year after initial study procedure

    Diagnostic yield of malignant conditions, being defined as a tissue biopsy allowing a definite diagnosis of a malignant condition in the lung

  2. Benign yield

    Time frame: One year after initial study procedure

    Diagnostic yield of non-malignant conditions, being defined as a tissue biopsy allowing a definite diagnosis of a benign condition in the lung

  3. NGS testing

    Time frame: One week after initial study procedure

    Proportion of patients with sufficient biopsy material for NGS testing

  4. Complications

    Time frame: One week after bronchoscopy

    Total proportion of patients with procedure complications

  5. Serious procedure complications

    Time frame: One week after bronchoscopy

    Total proportion of patients with severe procedure complications

  6. Feasibility of procedure

    Time frame: Same day as the study procedure

    Feasibility of procedure (proportion of procedures: not commenced, aborted due to respiratory failure, excessive coughing, inability to cooperate with the procedure, lesion not found, less than 10 forceps biopsies, less than 5 cryo biopsies

  7. tissue grading score

    Time frame: One week after initial study procedure

    The study will be using the "scoring system for specimen quality" https://doi.org/10.1159/000531010

    The study will assess the difference in mean or median tissue score. Min value 1, Maximum value 6. "1" represents the worst tissue specimen and "6" represents the best tissue specimen.

Study contacts

Contact information is provided by the study sponsor or research team.

Amanda D Juul, MD, PhD

CONTACT

[email protected]

+4565412727

Christian B Laursen, MD, Professor

CONTACT

[email protected]

Sponsors and collaborators

Lead sponsor

Odense University Hospital

Other

Collaborators

  • University of Southern Denmark

Registry information

Acronym: DR CRYO

Important dates

Study start
2025
Primary completion
2027
Study completion
2027
First posted
Feb 25, 2025
Registry last updated
May 20, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.